- Home
- JTAI vs SILO Comparison
JTAI vs SILO Comparison
Compare JTAI & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JTAI
- SILO
- Stock Information
- Founded
- JTAI 2018
- SILO 2010
- Country
- JTAI United States
- SILO United States
- Employees
- JTAI N/A
- SILO N/A
- Industry
- JTAI Blank Checks
- SILO Apparel
- Sector
- JTAI Finance
- SILO Consumer Discretionary
- Exchange
- JTAI Nasdaq
- SILO Nasdaq
- Market Cap
- JTAI 9.9M
- SILO 8.8M
- IPO Year
- JTAI N/A
- SILO N/A
- Fundamental
- Price
- JTAI $4.28
- SILO $1.13
- Analyst Decision
- JTAI
- SILO
- Analyst Count
- JTAI 0
- SILO 0
- Target Price
- JTAI N/A
- SILO N/A
- AVG Volume (30 Days)
- JTAI 236.7K
- SILO 139.4K
- Earning Date
- JTAI 03-27-2025
- SILO 05-12-2025
- Dividend Yield
- JTAI N/A
- SILO N/A
- EPS Growth
- JTAI N/A
- SILO N/A
- EPS
- JTAI N/A
- SILO N/A
- Revenue
- JTAI $14,022,628.00
- SILO $72,102.00
- Revenue This Year
- JTAI $16.46
- SILO $1.86
- Revenue Next Year
- JTAI $193.15
- SILO N/A
- P/E Ratio
- JTAI N/A
- SILO N/A
- Revenue Growth
- JTAI 14.80
- SILO N/A
- 52 Week Low
- JTAI $2.30
- SILO $0.77
- 52 Week High
- JTAI $217.80
- SILO $4.50
- Technical
- Relative Strength Index (RSI)
- JTAI 42.77
- SILO 32.12
- Support Level
- JTAI $3.95
- SILO $1.15
- Resistance Level
- JTAI $6.35
- SILO $1.39
- Average True Range (ATR)
- JTAI 0.62
- SILO 0.09
- MACD
- JTAI -0.13
- SILO -0.01
- Stochastic Oscillator
- JTAI 9.49
- SILO 1.68
About JTAI Jet.AI Inc.
Jet AI Inc is principally involved in the sale of jet cards, which enable holders to use certain aircraft owned, leased by, arranged, and/or managed by Jet Token and others at agreed-upon rates, as well as the sale of fractional interests in aircraft; and the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third party carriers as well as via Jet Token's leased and managed aircraft.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.